Skip to main content
. 2011 Aug 31;52(9):6919–6924. doi: 10.1167/iovs.10-5896

Table 1.

Demographic Information, Baseline Characteristics, Accompanying Immunosuppression, and Adverse Events of the Study Patients

Patient Sex Race Age at Enrollment (y) Diagnosis Immunosuppressive Medications at Enrollment Immunosuppressive Medications at Last Follow-Up Adverse Events (Related to Study Medication)*
001 M H 33 Chronic NG IU None Efalizumab Transient neutropenia, transient vision loss
002 F C 22 Chronic NG IU Pred 20 mg qd Efalizumab Transient ocular pain, transient skin rash
003 M AA 31 Pars Planitis Cell 1500 mg bid, Pred 15 mg qd, PF qid OU Efalizumab, Cell 1500 mg bid, Pred 15 mg qd, PF qid OU Transient lymphocytosis, URI and sore throat, transient headaches
004 F C 60 Chronic NG IU Cell 1000 mg bid Efalizumab; Cell 1000 mg bid; CSA 100 mg bid Hot flashes
005 M A 28 VKH Pred 5 mg qd CSA 100 mg bid AZA 50 mg qd Efalizumab, Pred 5 mg qd, CSA 50 mg bid Transient headaches, lymphocytosis, fatigue
006 F AA 82 Posterior scleritis with IU Cell 1000 mg bid, Pred 15 mg qd Efalizumab, Cell 500 mg bid, Pred 15 mg qd Lymphocytosis, ocular discomfort, dizziness and nausea

H, Hispanic; C, Caucasian; AA, African American; A, Asian; NG, nongranulomatous; IU, intermediate uveitis; VKH, Vogt-Koyanagi-Harada Syndrome; Pred, Prednisone; Cell, Cellcept (Genentech, S. San Francisco, CA); PF, Prednisolone acetate 1%; CSA, cyclosporine; AZA, azathioprine; bid, twice daily; qd, daily; qid, four times a day.

*

Adverse events deemed related to study medication.